---
title: "Weekly Recap: CSPC H1 profit jump and NMPA accepts KN026 & HB1801 NDAs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296712712.md"
description: "CSPC Pharmaceutical reported H1 revenue of RMB18.6B, up ~40%, with net profit surging ~139% driven by strong drug sales and record out-licensing fees. Additionally, China's NMPA accepted new drug applications for breast cancer therapies KN026 and HB1801."
datetime: "2026-08-23T23:13:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296712712.md)
  - [en](https://longbridge.com/en/news/296712712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296712712.md)
generator: "portal-rs"
---

# Weekly Recap: CSPC H1 profit jump and NMPA accepts KN026 & HB1801 NDAs

CSPC Pharmaceutical Group Limited (HKEX:1093) posted H1 revenue up ~40% to RMB18.6B and net profit up ~139% on strong finished drug sales, record out‑licensing fees, HK$321M buybacks and ongoing R&D, while NDAs for breast cancer therapies KN026 and HB1801 were accepted by China’s NMPA.

**Previous Week Recap**

-   **H1 Revenue Up ~40% Revenue**: CSPC Pharmaceutical (1093) H1 revenue rose ~40% to RMB18.6B; net profit up ~139% YoY. Strong finished drug sales, record out‑licensing fees, ongoing R&D and HK$321M buybacks. 2 sources
-   **NMPA Accepts Two NDAs**: CSPC Pharmaceutical (1093) said China’s NMPA accepted NDAs for two advanced breast cancer therapies, KN026 and HB1801; company disclosed acceptance only, no timelines or approval odds provided. Reuters

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [CSPC PHARMA  Marketing Application for Sirolimus for Injection Accepted](https://longbridge.com/en/news/293996689.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**